Advertisement

Use of Prophylaxis to Prevent Complications of Hemophilia

  • P. M. Mannucci
  • L. Mendolicchio
  • A. Gringeri
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 489)

Abstract

The main principle of treatment of hemophilia is the replacement of the deficient coagulation factor with plasma-derived or recombinant products. The goal of replacement therapy may be either the prompt arrest of bleeding (episodic or on demand treatment) or its prevention through the regular administration of factor (prophylaxis).

Keywords

Factor VIII Prophylactic Treatment Joint Damage Bleeding Episode Central Venous Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nilsson IM, Hedner U, Ahlberg A. Hemophilia prophylaxis in Sweden. Acta Paediat Scand 65: 129–135, 1976.PubMedCrossRefGoogle Scholar
  2. 2.
    Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophlia A and B. Acta Orthop Scand 77: 1–98, 1965).Google Scholar
  3. 3.
    Petrini P, Blomback M, Egberg N, Lindvall N. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediat Hematol Oncol 13: 280–287, 1991.CrossRefGoogle Scholar
  4. 4.
    Nilsson IM, Berntorp E, Lofquist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232: 25–32, 1992.PubMedCrossRefGoogle Scholar
  5. 5.
    Blanchette VS, Al-Musa A, Stain AM, Ingram J, Fille RM. Central venous access devices in children with hemophilia: an up-date. Blood Coag Fibrinol 8: S11–S14, 1997.Google Scholar
  6. 6.
    Ljung R, van den Berg M, Petrini P, Tengbom L, Scheibel E, Kekomaki R, Effenber W. Prot-ACath usage in children with haemophilia: experience of 53 cases. Acta Paedit 87:1051–1054, 1998.CrossRefGoogle Scholar
  7. 7.
    Lofquist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients. A long-term follow-up. J Intern Med 241: 395–400 1997.CrossRefGoogle Scholar
  8. 8.
    Bemtorp E. Methods of hemophilia care delivery: regular prophylaxis vs. episodic treatment. Haemophilia 1: 3–7, 1995.CrossRefGoogle Scholar
  9. 9.
    van den Berg HM, Nieuwenhuis HK, Mauser-Bunchoten EP, Rosendeal G. Haemophilia prophylaxis in the Netherlands. Sem Haematol 31: 13–15 (suppl. 2), 1994.Google Scholar
  10. 10.
    Liesner Rj, Hair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haem 92: 973–978, 1996.CrossRefGoogle Scholar
  11. 11.
    Lusher J. Prophylaxis in children with hemophilia: is it the optimal treatment? Thromb Hemostats 78: 726–729, 1997.Google Scholar
  12. 12.
    Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 47: 113–117, 1994.PubMedCrossRefGoogle Scholar
  13. 13.
    Smith PS, Teutsch SM, Schaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Paediat 129: 424–431, 1996.CrossRefGoogle Scholar
  14. 14.
    Szucs TD, Offner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 2: 211–217, 1996.CrossRefGoogle Scholar
  15. 15.
    Bohm RL, Avom J, Glynn RJ, Choodnovsky I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemostas 79: 932–937, 1998.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • P. M. Mannucci
    • 1
  • L. Mendolicchio
    • 1
  • A. Gringeri
    • 1
  1. 1.Angelo Bianchi Bonomi Hemophilia and Thrombosis CenterIRCCS Maggiore Hospital and University of MilanItaly

Personalised recommendations